Therapy for cryptococcal meningitis in patients with AIDS.

Area of Science:

• Infectious Diseases
• Mycology
• HIV/AIDS Medicine

Background:

• Cryptococcal meningitis is a significant opportunistic infection in patients with Acquired Immunodeficiency Syndrome (AIDS).
• Standard treatment with amphotericin B plus flucytosine has considerable failure (20%-30%) and recurrence (40%-60%) rates without suppressivetherapy.

Purpose of the Study:

• To review and compare the efficacy of fluconazole and other antifungal agents in treating cryptococcal meningitis in AIDS patients.
• To identify risk factors associated with poor outcomes in cryptococcal meningitis treatment.

Main Methods:

• Review of recent comparative studies evaluating fluconazole, a triazole antifungal.
• Analysis of treatment response rates and relapse data for different antifungal regimens.
• Identification of clinical and laboratory parameters predicting treatment failure.

Main Results:

• Fluconazole demonstrates response rates of 35%-60% in primary therapy, comparable to amphotericin B alone.
• Amphotericin B plus flucytosine may be superior to fluconazole monotherapy in acute treatment.
• Fluconazole is highly effective in suppressing relapses of cryptococcal meningitis.
• Poor outcome predictors include lethargy, high cerebrospinal fluid cryptococcal antigen titers, and low cerebrospinal fluid leukocyte counts.

Conclusions:

• Fluconazole is a valuable option for suppressing cryptococcal meningitis relapses in AIDS patients.
• Further research is needed for optimal management of acute disease and primary prophylaxis in this population.
• Itraconazole shows potential but requires more extensive investigation.